%0 Journal Article %A Xiaoyu Song %A Jiayi Ji %A Boris Reva %A Himanshu Joshi %A Anna Pamela Calinawan %A Madhu Mazumdar %A Emanuela Taioli %A Pei Wang %A Rajwanth Veluswamy %T Post-Anticoagulant D-dimer as a Highly Prognostic Biomarker of COVID-19 Mortality %D 2020 %R 10.1101/2020.09.02.20180984 %J medRxiv %P 2020.09.02.20180984 %X Importance Clinical biomarkers that accurately predict mortality are needed for the effective management of patients with severe COVID-19 illness.Objective To determine whether D-dimer levels after anticoagulation treatment is predictive of in-hospital mortality.Design Retrospective study using electronic health record data.Setting A large New York City hospital network serving a diverse, urban patient population.Participants Adult patients hospitalized for severe COVID-19 infection who received therapeutic anticoagulation for thromboprophylaxis between February 25, 2020 and May 31, 2020.Exposures Mean and trend of D-dimer levels in the 3 days following the first therapeutic dose of anticoagulation.Main Outcomes In-hospital mortality versus discharge.Results 1835 adult patients (median age, 67 years [interquartile range, 57-78]; 58% male) with PCR-confirmed COVID-19 who received therapeutic anticoagulation during hospitalization were included. 74% (1365) of patients were discharged and 26% (430) died in hospital. The study cohort was divided into four groups based on the mean D-dimer levels and its trend following anticoagulation initiation, with significantly different in-hospital mortality rates (p<0.001): 49% for the high mean-increase trend (HI) group; 27% for the high-decrease (HD) group; 21% for the low-increase (LI) group; and 9% for the low-decrease (LD) group. Using penalized logistic regression models to simultaneously analyze 67 variables (baseline demographics, comorbidities, vital signs, laboratory values, D-dimer levels), post-anticoagulant D-dimer groups had the highest adjusted odds ratios (ORadj) for predicting in-hospital mortality. The ORadj of in-hospital death among patients from the HI group was 6.58 folds (95% CI 3.81-11.16) higher compared to the LD group. The LI (ORadj: 4.06, 95% CI 2.23-7.38) and HD (ORadj: 2.37; 95% CI 1.37-4.09) groups were also associated with higher mortality compared to the LD group.Conclusions and Relevance D-dimer levels and its trend following the initiation of anticoagulation have high and independent predictive value for in-hospital mortality. This novel prognostic biomarker should be incorporated into management protocols to guide resource allocation and prospective studies for emerging treatments in hospitalized COVID-19 patients.Question Are D-dimer levels following therapeutic anticoagulation predictive of mortality in hospitalized COVID-19 patients?Finding In a retrospective study of 1835 adult COVID-19 patients who received therapeutic anticoagulation for thromboprophylaxis during hospitalization, 1365 (74%) patients were discharged and 470 (26%) died. Post-anticoagulant D-dimer levels and trends were significantly and independently predictive of mortality.Meaning Active monitoring of post-anticoagulant D-dimer levels in hospitalized COVID-19 patients is a novel strategy for stratifying individual risk of in-hospital mortality that can help guide resource allocation and prospective studies for emerging treatments for severe COVID-19 illness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Mount Sinai Institutional Review Board with approval number IRB-20-03334.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe did not generate new data, but used de-identified data from Mount Sinai Ware House, and the access of the data is regulated by Mount Sinai. %U https://www.medrxiv.org/content/medrxiv/early/2020/09/03/2020.09.02.20180984.full.pdf